IRIS
ROTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.089
EU - Europa 2.855
AS - Asia 2.082
SA - Sud America 298
AF - Africa 47
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.379
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.033
IT - Italia 777
SG - Singapore 777
CN - Cina 740
IE - Irlanda 487
SE - Svezia 355
HK - Hong Kong 322
DE - Germania 320
BR - Brasile 275
FI - Finlandia 185
NL - Olanda 163
UA - Ucraina 140
FR - Francia 101
AT - Austria 92
TR - Turchia 91
RU - Federazione Russa 70
GB - Regno Unito 67
IN - India 56
CA - Canada 37
CI - Costa d'Avorio 29
BE - Belgio 24
BD - Bangladesh 23
CZ - Repubblica Ceca 15
PL - Polonia 13
IR - Iran 11
JP - Giappone 11
ID - Indonesia 8
AR - Argentina 7
MX - Messico 7
PK - Pakistan 7
AU - Australia 6
ES - Italia 6
IQ - Iraq 6
PA - Panama 6
JM - Giamaica 5
LT - Lituania 5
LU - Lussemburgo 5
RO - Romania 5
VN - Vietnam 5
CH - Svizzera 4
KR - Corea 4
MA - Marocco 4
UY - Uruguay 4
ZA - Sudafrica 4
CO - Colombia 3
DZ - Algeria 3
HU - Ungheria 3
PH - Filippine 3
RS - Serbia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
VE - Venezuela 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
NG - Nigeria 1
NR - Nauru 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 8.379
Salva come PNG Salva come JPEG
Città #
Singapore 503
Dublin 487
Chandler 472
Ashburn 389
Hong Kong 319
Santa Clara 254
Parma 243
Boardman 187
Beijing 145
Jacksonville 135
Ann Arbor 126
Dearborn 105
Munich 95
Princeton 90
Nanjing 84
Vienna 79
Shanghai 76
Izmir 72
Wilmington 62
Helsinki 55
Bologna 53
Grafing 53
San Mateo 50
Shenyang 49
Marseille 48
Jinan 44
Milan 44
Nanchang 42
New York 42
Moscow 39
Columbus 37
Hebei 32
Los Angeles 32
Hefei 30
Turku 30
Abidjan 29
Seattle 27
Toronto 26
Verona 24
Kunming 22
Brussels 21
Des Moines 21
Guangzhou 21
São Paulo 21
Amsterdam 20
Changsha 20
Nuremberg 20
Tianjin 20
Modena 19
Pune 19
Dallas 18
Bremen 17
Reggio Emilia 17
The Dalles 17
Frankfurt am Main 16
Fremont 16
Jiaxing 16
Rome 15
Chicago 14
West Jordan 14
Norwalk 13
Perugia 13
Rio de Janeiro 13
Brno 12
Düsseldorf 12
Houston 12
Bengaluru 11
Quattro Castella 11
Woodbridge 11
Florence 10
Hangzhou 10
London 10
Brescia 9
Carpi 9
Chongqing 9
Haikou 9
Trento 9
Zhengzhou 9
Belo Horizonte 8
Brooklyn 8
Council Bluffs 8
Jakarta 8
Kocaeli 8
Auburn Hills 7
Istanbul 7
Ningbo 7
San Francisco 7
Turin 7
Brasília 6
Charlotte 6
Guarulhos 6
Malo 6
Phoenix 6
Warsaw 6
Atlanta 5
Bolzano 5
Chengdu 5
Lanzhou 5
Mestre 5
Montreal 5
Totale 5.426
Salva come PNG Salva come JPEG
Nome #
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 159
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia 145
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 141
Targeting oncogenic Notch signaling with SERCA inhibitors 140
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 120
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 119
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 116
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 115
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 112
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 112
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis 112
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 108
Angiopoietins expression by human myeloma cells 108
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 107
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 104
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 103
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 102
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 97
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 96
227P Sexual dimorphism in immune profile of early and advanced NSCLC 96
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 96
Osteopontin is produced by human multiple myeloma cells 93
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 93
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 92
IL-7 is produced by myeloma cells in presence of IL-6 92
Acute lymphoblastic leukaemia in Noonan syndrome. 90
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 90
Multiple myeloma patient with unusual extramedullary involvement 87
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 87
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 85
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 85
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 84
Targeting Notch Trafficking and Processing in Cancers 84
Multiple Myeloma patient with unusual extramedullary involvement 83
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 83
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 82
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 82
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 82
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 82
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia 82
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis 80
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 80
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 80
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 78
Activating somatic and germline TERT promoter variants in myeloid malignancies 78
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 77
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 76
Multiple myeloma patient with unusual extramedullary involvement 76
IL-7 is produced by myeloma cells in presence of IL-6 75
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia 75
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 74
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling 74
Genetic and proteomic approaches to identify cancer drug targets. 73
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells 73
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 72
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 72
Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia 72
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 72
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES 72
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia 71
Leukemia-specific delivery of mutant NOT CH1 targeted therapy 70
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 68
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 67
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia 67
WO/2016/073708 67
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 66
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 65
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 65
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro 64
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 64
SERCA MODULATION COUNTERACTS GLUCOCORTICOID RESISTANCE IN T-ALL 63
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 62
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 62
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 61
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 61
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes 61
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 61
Acute lymphoblastic leukaemia 60
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 60
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. 58
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 58
CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders 57
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 54
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. 52
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma 52
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights 52
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 51
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 50
DHPLC analysis of NPM1 mutations in adult primary AML. 50
Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: From current standards to precision medicine 49
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E 49
SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520 47
Targeting NOTCH1 in hematopoietic malignancy. 46
T(10;11)(P13;P14-21) PICALM-MLLT10 ACUTE LEUKEMIA: CHARACTERIZATION OF TWO CASES WITH DIFFERENT PHENOTYPIC PRESENTATION 45
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 45
Genetic pathways in low-and high-grade HCV-related lymphomas are different 45
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. 45
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement 45
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 44
The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies 44
Totale 7.798
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021515 16 33 38 20 56 17 34 23 128 47 78 25
2021/2022517 16 16 11 15 7 64 72 55 27 40 32 162
2022/20231.922 219 191 106 124 206 206 32 117 585 7 82 47
2023/2024987 50 64 29 41 85 184 124 80 40 72 72 146
2024/20253.056 90 164 215 235 337 246 145 137 350 251 275 611
2025/2026305 305 0 0 0 0 0 0 0 0 0 0 0
Totale 8.548